The START-NEW-ERA phase II trial evaluated the effectiveness and safety of SAbR as a treatment option for LA-NSCLC pts who were unsuitable for ChT-RT. The study suggested that exclusive SAbR can provide effective local control and promising survival outcomes with minimal toxicity for LA-NSCLC pts who cannot undergo concurrent chemo-radiotherapy. In an initial […]...
ELCC 2023
Coverage of European Lung Cancer Congress 2023
Mar 29
-Apr 01, 2023